clinical trials

CRISPR Therapeutics gains FDA approval for Casgevy, its first gene-editing therapy for rare blood disorders, validating the platform with multiple pipeline candidates in development.

Peer-reviewed study validates Beyond Air's high-dose inhaled nitric oxide for treating respiratory infections including pneumonia, COVID-19, and bronchiolitis, supporting regulatory advancement.

ORBIMED Advisors divested 5.4 million Terns Pharma shares worth $125 million despite the stock's 858% annual gain, reducing its stake as the biotech company advances clinical programs.

Orchestra BioMed will present at two major healthcare investor conferences in March 2026, engaging with institutional investors on strategy and clinical progress.

Eupraxia Pharmaceuticals raises $55M via public offering to advance EP-104GI for eosinophilic esophagitis through Phase 2/3 development and expand GI pipeline.

Sensei Biotherapeutics stock surged 230% after acquiring Faeth Therapeutics and securing $200M investment, expanding its oncology pipeline with PIKTOR therapy.

Over 40 companies develop 50+ CTLA-4 inhibitor candidates for cancer immunotherapy. Recent FDA approvals and focus on combination strategies drive pipeline expansion.

Over 50 companies compete in the checkpoint inhibitor market with 60+ drug candidates in development. Major consolidation and innovation drive immuno-oncology growth through 2026.

Biotech firms advance treatment-resistant cancer therapies across multiple platforms, including oncolytic viruses and cellular immunotherapy, with several candidates achieving regulatory milestones and encouraging clinical data.

Viking Therapeutics advances obesity drug VK2735 through phase 3 trials, expecting 2026 trial data. Dual GIP/GLP-1 agonist targets $100B+ market opportunity.

Perspective Therapeutics will release 2025 financial results and clinical pipeline updates on March 16, highlighting progress in its cancer-targeting radiopharmaceutical programs.

Oculis appoints Katie Kazem as Chief Legal Officer. She brings 15+ years of life sciences legal expertise to support the company's three late-stage clinical programs.

Oculis appoints seasoned legal executive Katie Kazem as Chief Legal Officer to strengthen governance as it advances clinical pipeline with late-stage therapeutic candidates.

12+ companies advance iPSC-derived NK cell therapies for cancer treatment. Century Therapeutics and Fate Therapeutics report promising clinical progress in this expanding immunotherapy field.

Human microbiome market expected to grow nearly fourfold to $3.27B by 2035, driven by advancing sequencing technology and 215+ therapeutic candidates in clinical development.

Maze Therapeutics CMO sold 15,000 shares via pre-arranged plan, completing divestiture. He retains 300,000 options while company maintains positive clinical momentum.

BioRestorative raised $5M through equity offering to advance stem cell therapies, including BRTX-100 for spine disease and metabolic disorder research.

CRISPR Therapeutics eyes growth from Casgevy commercialization and pipeline expansion. FDA-approved gene therapy generates revenue while multiple clinical programs advance toward 2026 milestones.

Eli Lilly acquires Orna Therapeutics for $2.4B to gain circular RNA gene therapy technology and autoimmune disease candidates, strengthening its pipeline.